New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 29, 2013
06:06 EDTIMUCImmunoCellular allows IND for ICT-140
ImmunoCellular Therapeutics announced that the FDA has allowed the investigational new drug, or IND, application for ICT-140, paving the way for conducting a clinical trial. ICT-140 is a dendritic cell vaccine targeting seven antigens that are over-expressed in ovarian cancer, as well as cancer stem cells. ImmunoCellular filed the IND application with the FDA in the Q4 of FY12, as planned.
News For IMUC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 23, 2015
16:23 EDTIMUCImmunoCellular to hold a conference call on ICT-107
Subscribe for More Information
November 20, 2015
06:05 EDTIMUCImmunoCellular presents updated ICT-107 Phase 2 immune response data
ImmunoCellular Therapeutics announced the presentation of recently updated overall survival, or OS, results and immune response data from the phase 2 trial of ICT-107 in patients with newly diagnosed glioblastoma. ICT-107 is a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells. The data are being presented at the 20th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology, being held in San Antonio, TX. The data from the phase 2 trial continue to indicate a survival advantage in the ICT-107 treated group compared to the control group. The data also show a significant association between immune response and survival, especially in HLA-A2 positive, or HLA-A2+, patients, which is the target patient population for the phase 3 registration trial.
November 12, 2015
06:05 EDTIMUCImmunoCellular enters sponsored research agreement with MD Anderson
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use